Anika Therapeutics, Inc. (ANIK)Healthcare | Drug Manufacturers - Specialty & Generic | Bedford, United States | NasdaqGS
20.47 USD
|
Hot Take ↕ | Oct. 10, 2026, 6:17 a.m. EDT
The investment case here is fundamentally broken despite the recent headline of 'profit returns.' While revenue grew 16% in the latest quarter, the business has been a structural disaster over the last decade, erasing roughly 81% of its value since 2016. The market has correctly identified that the company is trapped in a cycle of losses with negative returns on equity and assets, making the current valuation a trap rather than a bargain. The lack of any dividend policy leaves investors exposed to pure capital loss risk. Furthermore, the options market is screaming 'sell'; the sheer volume of put open interest suggests smart money is betting on a continued decline or a catastrophic drop, completely ignoring the modest analyst upgrades. With a beta of only 0.21, the stock lacks the volatility required for a speculative bounce, and without a proven path to sustained profitability, the long-term outlook remains bleak. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.272431 |
| AutoETS | 0.277647 |
| MSTL | 0.283937 |
| AutoTheta | 0.288545 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 2.56 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.393 |
| Revenue per Share | 8.687 |
| Market Cap | 273,949,312 |
| Forward P/E | 21.55 |
| Beta | 0.21 |
| Profit Margins | -3.14% |
| Website | https://www.anika.com |
As of Oct. 10, 2026, 6:17 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes 7.5 and 22.5) compared to negligible call volume. This indicates a strong consensus expectation of further price weakness or a significant gap-down event, rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2371585 |
| Address1 | 32 Wiggins Avenue |
| All Time High | 75.72 |
| All Time Low | 0.6875 |
| Ask | 26.22 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 116,470 |
| Average Daily Volume3 Month | 101,256 |
| Average Volume | 101,256 |
| Average Volume10Days | 116,470 |
| Beta | 0.21 |
| Bid | 20.61 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 10.258 |
| City | Bedford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.47 |
| Current Ratio | 4.479 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 20.77 |
| Day Low | 20.0 |
| Debt To Equity | 18.393 |
| Display Name | Anika Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,328,200 |
| Earnings Call Timestamp Start | 1,785,328,200 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | 3,040,000 |
| Ebitda Margins | 0.0252 |
| Enterprise To Ebitda | 85.785 |
| Enterprise To Revenue | 2.161 |
| Enterprise Value | 260,787,312 |
| Eps Current Year | 1.05 |
| Eps Forward | 0.95 |
| Eps Trailing Twelve Months | -0.23 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 781 305 9720 |
| Fifty Day Average | 20.6876 |
| Fifty Day Average Change | -0.21759987 |
| Fifty Day Average Change Percent | -0.010518372 |
| Fifty Two Week Change Percent | 123.71585 |
| Fifty Two Week High | 22.88 |
| Fifty Two Week High Change | -2.4099998 |
| Fifty Two Week High Change Percent | -0.105332166 |
| Fifty Two Week Low | 8.67 |
| Fifty Two Week Low Change | 11.799999 |
| Fifty Two Week Low Change Percent | 1.3610148 |
| Fifty Two Week Range | 8.67 - 22.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 736,435,800,000 |
| Float Shares | 11,285,320 |
| Forward Eps | 0.95 |
| Forward P E | 21.547367 |
| Free Cashflow | 3,062,375 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 235 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 20.47 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.62165 |
| Gross Profits | 75,004,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06403 |
| Held Percent Institutions | 0.93649 |
| Implied Shares Outstanding | 13,382,966 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts. |
| Long Name | Anika Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 273,949,312 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_328641 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -3,121,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 273,681,654 |
| Number Of Analyst Opinions | 2 |
| Open | 20.47 |
| Operating Cashflow | 5,977,000 |
| Operating Margins | 0.114259996 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.06 |
| Phone | 781 457 9000 |
| Previous Close | 20.47 |
| Price Eps Current Year | 19.49524 |
| Price Hint | 2 |
| Price To Book | 1.9955156 |
| Price To Sales Trailing12 Months | 2.2705364 |
| Profit Margins | -0.03136 |
| Quick Ratio | 3.047 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 20.77 |
| Regular Market Day Low | 20.0 |
| Regular Market Day Range | 20.0 - 20.77 |
| Regular Market Open | 20.47 |
| Regular Market Previous Close | 20.47 |
| Regular Market Price | 20.47 |
| Regular Market Time | 1,791,916,785 |
| Regular Market Volume | 62,863 |
| Return On Assets | -0.00873 |
| Return On Equity | -0.02191 |
| Revenue Growth | 0.156 |
| Revenue Per Share | 8.687 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 13,382,966 |
| Shares Percent Shares Out | 0.0274 |
| Shares Short | 367,155 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 345,448 |
| Short Name | Anika Therapeutics Inc. |
| Short Percent Of Float | 0.036 |
| Short Ratio | 4.53 |
| Source Interval | 15 |
| State | MA |
| Symbol | ANIK |
| Target High Price | 23.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 23.0 |
| Target Median Price | 23.0 |
| Total Cash | 38,412,000 |
| Total Cash Per Share | 2.87 |
| Total Debt | 25,250,000 |
| Total Revenue | 120,654,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.23 |
| Trailing Peg Ratio | 2.1526 |
| Triggerable | 1 |
| Two Hundred Day Average | 15.28215 |
| Two Hundred Day Average Change | 5.187849 |
| Two Hundred Day Average Change Percent | 0.33947113 |
| Type Disp | Equity |
| Volume | 62,863 |
| Website | https://www.anika.com |
| Zip | 1,730 |